Cancer Drug Resistance
All Journals
Search
Log In
Editor-in-Chief:
Godefridus J. Peters
Indexing:
ESCI
,
PMC
,
Scopus
,
CAS
,
CNKI
,
Dimensions
,
Lens
,
Embase
,
Journal Rank:
Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)]
Submission to first decision:
63 days
Journal Flyer
Hot Keywords
Resistance
Drug delivery
Nanomedicine
Tumor microenvironment
Immune checkpoint inhibitors
Target therapy
Immunotherapy
Radiotherapy
Ferroptosis
PARP inhibitors
MYC
ABC transporters
Autophagy
Metabolism
Mechanisms
Precision medicine
Extracellular vesicles
Stem cell
Biomarker
Ovarian cancer
Renal cell carcinoma
Prostate cancer
Breast cancer
Colorectal cancer
Myeloid leukemia
Non-small cell lung cancer
Pancreatic cancer
Head and neck cancer
Squamous cell carcinoma
Mitochondria
Home
About
About the Journal
Aims and Scope
Editorial Policies
Editorial Board
Junior Editorial Board
News
Journal History
Partners
Advertise
Contact Us
Publish with us
For Authors
Author Instructions
Article Processing Charges
Editorial Process
Manuscript Templates
Submit a Manuscript
For Reviewers
Peer Review Guidelines
Articles
All Articles
Articles with Video Abstracts
Video Abstract Guidelines
Articles Ebooks
Special Issues
All Special Issues
Ongoing Special Issues
Special Issue Ebooks
Special Issue Guidelines
Special Collections
Volumes
Pre-onlines
Features
Webinars
Academic Talks
Interviews
Home
Articles
Special Issues
Volumes
Webinars
Videos
Menu
Cancer Drug Resistance
Search
Submit
Editor-in-Chief:
Godefridus J. Peters
Journal Rank:
Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)]
Submission to first decision:
63 days
Home
Articles
Special Issues
Volumes
Webinars
Videos
Menu
Home
Volumes
Volume7, Issue-1 (2024)
Volume
Current applications of tumor local ablation (TLA) combined with immune checkpoint inhibitors in breast cancer treatment
Cancer-associated fibroblast cell surface markers as potential biomarkers or therapeutic targets in lung cancer
Research progress on the role and mechanism of circular RNA in drug resistance of head and neck squamous cell carcinoma
The role of circRNAs and miRNAs in drug resistance and targeted therapy responses in breast cancer
The uniqueness of ABCB5 as a full transporter ABCB5FL and a half-transporter-like ABCB5β
Targeting NETosis: nature’s alarm system in cancer progression
Impact of genetic variants in the solute carrier (<i>SLC</i>) genes encoding drug uptake transporters on the response to anticancer chemotherapy
Unraveling the complexity of drug resistance mechanisms to SINE, T cell-engaging therapies and CELMoDs in multiple myeloma: a comprehensive review
Inhibition of glutaminolysis alone and in combination with HDAC inhibitor has anti-myeloma therapeutic effects
Recent advanced lipid-based nanomedicines for overcoming cancer resistance
The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer
Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer
Validation of single nucleotide polymorphisms potentially related to R-CHOP resistance in diffuse large B-cell lymphoma patients
ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies
Chemosensitizing effect of pentoxifylline in sensitive and multidrug-resistant non-small cell lung cancer cells
Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them
Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers
Isocucurbitacin B inhibits glioma growth through PI3K/AKT pathways and increases glioma sensitivity to TMZ by inhibiting hsa-mir-1286a
Emerging role of MYB transcription factors in cancer drug resistance
HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs
The therapeutic potential of circular RNA in triple-negative breast cancer
Mechanisms underlying reversed TRAIL sensitivity in acquired bortezomib-resistant non-small cell lung cancer cells
Dysregulation of calcium homeostasis in cancer and its role in chemoresistance
Overcoming immuno-resistance by rescheduling anti-VEGF/cytotoxics/anti-PD-1 combination in lung cancer model
Circular RNA circNCOA3 promotes tumor progression and anti-PD-1 resistance in colorectal cancer
Regulation of Nrf2/Keap1 signaling pathway in cancer drug resistance by galectin-1: cellular and molecular implications
Leveraging genomics, transcriptomics and epigenomics to understand chemoimmunotherapy resistance in chronic lymphocytic leukemia
Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors
Reactive oxygen species and its role in pathogenesis and resistance to therapy in acute myeloid leukemia
Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer
Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel
Targeting T regulatory (T<sub>reg</sub>) cells in immunotherapy-resistant cancers
Acquisition of drug resistance in endothelial cells by tumor-derived extracellular vesicles and cancer progression
Actions for 0 selected articles
Download PDFs >
Cancer Drug Resistance
ISSN 2578-532X (Online)
editorial@cdrjournal.com
Navigation
Contact Us
Sitemap
Follow Us
LinkedIn
Twitter
WeChat
Navigation
Contact Us
Sitemap
Committee on Publication Ethics
https://publicationethics.org/members/cancer-drug-resistance
Portico
All published articles will preserved here permanently:
https://www.portico.org/publishers/oae/
Committee on Publication Ethics
https://publicationethics.org/members/cancer-drug-resistance
Portico
All published articles will preserved here permanently:
https://www.portico.org/publishers/oae/